Open an account

AnaptysBio

ANAB · NASDAQ

$45.43−$3.81 (−7.74%)TodayMarket closed ·
Prev close $49.24

About ANAB

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The firm's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The firm's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).

Employees
104
Headquarters
San Diego, California
Listed
Jan 26, 2017
Sector
Health Care
Industry
Biotechnology
Website
anaptysbio.com

ANAB key statistics

Market cap
1.36B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
579.80K
Volume
1.21M
Open price
$49.57
High today
$51.86
Low today
$44.02
52 Week high
$72.36
52 Week low
$20.18

AnaptysBio (ANAB) at a glance

As of Oct 20, 2026, AnaptysBio (ANAB) shares are priced at $45.43, giving the company a market cap of 1.36B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $44.02 and $51.86. The current price is 3.2% above the day's low and 12.4% below its high.

Volume so far is 1.21M shares, above the average of 579.80K shares a day.

Over the past year AnaptysBio has ranged from $20.18 to $72.36, and now sits 48% of the way up that range.

AnaptysBio met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $0.07 per share against an estimate of $0.0031.

The average analyst price target is $91.67, 101.8% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 13 analyst ratings say Buy
  • Buy92.3%
  • Hold7.7%
  • Sell0.0%
Price target · 11 analystsAvg $91.67
Low
$75.75
Now
$45.43
High
$147.00

ANAB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 410.3% on average.

  1. Q3 FY24: reported -$1.14 per share against an estimate of -$1.68
  2. Q4 FY24: reported -$0.72 per share against an estimate of -$1.65
  3. Q1 FY25: reported -$1.28 per share against an estimate of -$1.28
  4. Q2 FY25: reported -$1.34 per share against an estimate of -$1.57
  5. Q3 FY25: reported $0.52 per share against an estimate of -$1.47
  6. Q4 FY25: reported $1.58 per share against an estimate of $0.9573
  7. Q1 FY26: reported -$1.84 per share against an estimate of -$0.6159
  8. Q2 FY26: reported $0.07 per share against an estimate of $0.0031

ANAB news

  • Press releaseGlobe Newswire

    A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

  • Press releasePRNewswire

    Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

  • Vandana Singh

    AnaptysBio Stock Rallies As Delaware Court Tosses Tesaro Breach Claim

  • Press releasePRNewswire

    Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

  • Vandana Singh

    AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties

  • Press releasePRNewswire

    Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

  • Vandana Singh

    GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

Similar companies

Companies in the same industry as AnaptysBio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.